Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: May 29, 2026

Murine Bilateral Renal Lymphadenectomy

Murine Bilateral Renal Lymphadenectomy

Published on: December 30, 2025

Lymph node dissection in renal cell carcinoma.

Umberto Capitanio¹, Frank Becker, Michael L Blute

¹University Vita-Salute San Raffaele, Department of Urology, Milan, Italy. capitanio.umberto@hsr.it

European Urology

|September 24, 2011

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Higher functional-longevity genomic merit is associated with lower morbidity, shorter calving interval, and greater herd retention in Holstein cows matched for milk-production merit.

Journal of dairy science·2026

Same author

Medical complications in children with central nervous system injuries during inpatient rehabilitation.

Journal of rehabilitation medicine·2026

Same author

From Evidence to Implementation: How Should We Screen for Prostate Cancer in the Modern Era?: Editorial to: Nguyen DD, Tadayon B, Lin L, et al. Effect of Prostate Cancer Screening with Prostate-specific Antigen Testing on Long-term Prostate Cancer-specific Mortality: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Eur Urol. 2026. In press. https://doi.org/10.1016/j.eururo.2026.04.005.

European urology·2026

Same author

Targeted and Perilesional or Systematic Biopsies in Prostate Cancer: The TARGET Clinical Trial Protocol.

European urology oncology·2026

Same author

A neuregulin-like ligand and EGF receptor underpin <i>Echinococcus multilocularis</i> development.

Frontiers in cellular and infection microbiology·2026

Same author

External validation and comparison of nomograms for prediction of long-term disease recurrence and survival for bladder cancer patients who undergo radical cystectomy.

Minerva urology and nephrology·2026

Lymph node dissection (LND) may benefit select renal cell carcinoma (RCC) patients with advanced disease or high-risk features. However, for early-stage, node-negative RCC, LND offers limited staging information and no survival advantage.

Area of Science:

Urology
Oncology
Surgical Pathology

Background:

Lymphadenectomy (lymph node dissection [LND]) is standard for detecting lymph node invasion (LNI) in renal cell carcinoma (RCC).
The therapeutic benefit of LND in RCC remains controversial, despite its accuracy in staging.

Purpose of the Study:

To review existing literature on the role of LND in RCC staging and patient outcomes.
To evaluate the diagnostic and therapeutic implications of LND in various RCC risk groups.

Main Methods:

A comprehensive Medline search identified relevant original articles, reviews, and editorials on LND in RCC.
Articles were critically reviewed by an expert panel, prioritizing those with the highest level of evidence.

Main Results:

Related Experiment Videos

Last Updated: May 29, 2026

Murine Bilateral Renal Lymphadenectomy

Murine Bilateral Renal Lymphadenectomy

Published on: December 30, 2025

Renal lymphatic drainage is unpredictable, and current imaging techniques have limitations in detecting small lymph node metastases.
A key trial showed no LND benefit for node-negative RCC patients with low LNI risk.
Retrospective studies suggest LND may benefit high-risk RCC patients (e.g., advanced stage, high grade, sarcomatoid features).

Conclusions:

Extended LND may benefit patients with locally advanced or high-risk RCC when feasible.
Regional LND might offer a survival benefit for node-positive patients, though often they have distant metastases.
For early-stage, node-negative RCC without adverse features, LND provides minimal staging value and no survival benefit.